MYGN

Myriad Genetics (MYGN)

About Myriad Genetics (MYGN)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Details

Daily high
$26.49
Daily low
$25.90
Price at open
$26.49
52 Week High
$29.30
52 Week Low
$13.82
Market cap
2.4B
Dividend yield
0.00%
Volume
2
Avg. volume
658,954
P/E ratio
-14.48

Myriad Genetics News

Details

Daily high
$26.49
Daily low
$25.90
Price at open
$26.49
52 Week High
$29.30
52 Week Low
$13.82
Market cap
2.4B
Dividend yield
0.00%
Volume
2
Avg. volume
658,954
P/E ratio
-14.48